

Filter: minimal size of the groups n = 5

EQA round: VVV1/21 - Maternal Diagnostic Screening (Triple Test)

Deadline: 23.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(238) free beta-hCG														
Samples and groups		[U/L]			49							47	47	100%
Sample A1														
(24) B.R.A.H.M.S.		54,9	3,3	6,0	49							47	47	100%
(60) Roche		58,8	2,4	4,0	10	0	CVPG	58,8	1,8	15%	49,9	67,7	10	
Other		54,1	2,7	5,0	37	0	CVPG	54,1	1,1	15%	45,9	62,3	37	
					2	0							0	
								1x 36, 1x 179						
Sample B1														
(24) B.R.A.H.M.S.		54,3	3,2	5,9	49							47	47	100%
(60) Roche		56,7	2,5	4,5	10	0	CVPG	56,7	2,0	15%	48,1	65,3	10	
Other		53,9	2,9	5,4	37	0	CVPG	53,9	1,2	15%	45,8	62	37	
					2	0							0	
								1x 36, 1x 179						
(239) PAPP-A														
Samples and groups		[U/L]			52							48	48	100%
Sample A1														
(24) B.R.A.H.M.S.		1,22	0,063	5,1	52							48	48	100%
(60) Roche		1,23	0,037	3,0	11	0	CVPG	1,23	0,027	15%	1,04	1,42	11	
Other		1,21	0,063	5,2	37	0	CVPG	1,21	0,026	15%	1,02	1,4	37	
					4	0							0	
								2x 29, 1x 36, 1x 179						
Sample B1														
(24) B.R.A.H.M.S.		0,390	0,02	5,0	52							48	48	100%
(60) Roche		0,384	0,014	3,8	11	0	CVPG	0,384	0,011	15%	0,326	0,442	11	
Other		0,389	0,02	5,2	37	0	CVPG	0,389	0,081	15%	0,33	0,448	37	
					4	0							0	
								2x 29, 1x 36, 1x 179						
(245) PIGF														
Samples and groups		[ng/L]			22							22	21	95%
Sample A1														
(24) B.R.A.H.M.S.		26,5	3,9	15	22							22	21	95%
(60) Roche		22,3	1,0	4,6	7	0	CVPG	22,3	0,99	20%	17,8	26,8	7	
Other		28,2	2,8	9,9	15	0	CVPG	28,2	1,8	20%	22,5	33,9	15	
Sample B1														
(24) B.R.A.H.M.S.		19,7	2,9	15	22							22	21	95%
(60) Roche		17,3	2,4	14	7	0	CVPG	17,3	2,4	20%	13,8	20,8	7	
Other		20,7	2,4	12	15	0	CVPG	20,7	1,5	20%	16,5	24,9	15	
								2x 29, 1x 36, 1x 179						
Set 2														
(370) AFP														
Samples and groups		[µg/L]			47							38	36	95%
Sample A2														
(1) Abbott		6,85	0,73	11	47							38	37	97%
(12) Beckman Coulter		6,54	0,39	6,0	5	0	CVPG	6,54	1,1	20%	5,23	7,85	5	
(60) Roche		6,73	0,69	10	18	0	CVPG	6,73	0,40	20%	5,38	8,08	18	
Other		7,15	0,69	9,6	15	0	CVPG	7,15	0,44	20%	5,72	8,58	15	
					9	0							0	
								2x 24, 3x 29, 1x 162, 3x 179						
Sample B2														
(1) Abbott		31,2	3,1	9,9	47							38	36	95%
(12) Beckman Coulter		30,7	0,52	1,7	5	0	CVPG	30,7	1,5	20%	24,5	36,9	5	
(60) Roche		29,4	2,1	7,2	18	0	CVPG	29,4	1,2	20%	23,5	35,3	18	
Other		33,4	2,1	6,3	15	0	CVPG	33,4	1,3	20%	26,7	40,1	15	
					9	0							0	
								2x 24, 3x 29, 1x 162, 3x 179						
(373) hCG														
Samples and groups		[kU/L]			46							37	34	92%
Sample A2														
(1) Abbott		110	27	24	46							37	35	95%
(12) Beckman Coulter		108	5,6	5,2	5	0	CVPG	108	16	18%	88,5	128	5	
(60) Roche		132	14	11	18	0	CVPG	132	8,1	18%	108	156	18	
Other		93,3	9,3	10	14	0	CVPG	93,3	6,1	18%	76,5	111	14	
					9	0							0	
								1x 24, 3x 29, 1x 36, 1x 162, 3x 179						
Sample B2														
(1) Abbott		34,3	7,0	20	46							37	36	97%
(12) Beckman Coulter		32,3	1,5	4,7	5	0	CVPG	32,3	4,3	18%	26,4	38,2	5	
(60) Roche		40,4	3,4	8,3	18	0	CVPG	40,4	1,9	18%	33,1	47,7	18	
Other		29,4	2,2	7,6	14	0	CVPG	29,4	1,5	18%	24,1	34,7	14	
					9	0							0	
								1x 24, 3x 29, 1x 36, 1x 162, 3x 179						
(375) Estriol unconjug.														
Samples and groups		[nmol/L]			35							34	28	82%
Sample A2														
(12) Beckman Coulter		0,384	0,16	41	35							34	29	85%
		0,456	0,11	24	22	0	CVPG	0,456	0,058	33%	0,305	0,607	22	

Filter: minimal size of the groups n = 5

EQA round: VVV1/21 - Maternal Diagnostic Screening (Triple Test)

Deadline: 23.04.2021

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(375) Estriol unconjug.	[nmol/L]				35								34	28	82%
Samples and groups															
Sample A2		0,384	0,16	41	35								34	29	85%
(29) Siemens (Immulite)		0,241	0,002	1,1	12	0	CVPG	0,241	0,0019	33%	0,161	0,321			12
Other					1	0									0
															1x 999
Sample B2		2,60	0,94	36	35								34	33	97%
(12) Beckman Coulter		3,11	0,31	10	22	0	CVPG	3,11	0,16	33%	2,08	4,14			22
(29) Siemens (Immulite)		1,55	0,37	24	12	0	CVPG	1,55	0,27	33%	1,03	2,07			12
Other					1	0									0
															1x 999
1. trimester															
(240) free beta-hCG (MoM)	[MoM]				44								42	40	95%
Samples and groups															
Mother X1		1,24	0,14	11	44								42	40	95%
(24) B.R.A.H.M.S.		1,26	0,11	8,5	10	0	CVPG	1,26	0,083	33%	0,844	1,68			10
(60) Roche		1,23	0,15	12	32	0	CVPG	1,23	0,063	33%	0,824	1,64			32
Other					2	0									0
															1x 36, 1x 179
Mother Y1		1,56	0,20	13	44								42	40	95%
(24) B.R.A.H.M.S.		1,54	0,15	9,8	10	0	CVPG	1,54	0,12	33%	1,03	2,05			10
(60) Roche		1,58	0,21	13	32	0	CVPG	1,58	0,092	33%	1,05	2,11			32
Other					2	0									0
															1x 36, 1x 179
(241) PAPP-A (MoM)	[MoM]				48								45	42	93%
Samples and groups															
Mother X1		0,533	0,059	11	48								45	45	100%
(24) B.R.A.H.M.S.		0,521	0,039	7,4	11	0	CVPG	0,521	0,029	33%	0,349	0,693			11
(60) Roche		0,531	0,064	12	34	0	CVPG	0,531	0,027	33%	0,355	0,707			34
Other					3	0									0
															1x 29, 1x 36, 1x 179
Mother Y1		0,108	0,009	8,9	48								45	42	93%
(24) B.R.A.H.M.S.		0,100	0,000	0,00	11	5	CVPG	0,1		33%	0,067	0,133			11
(60) Roche		0,109	0,008	7,9	34	8	CVPG	0,109	0,0042	33%	0,073	0,145			34
Other					3	1									0
															1x 29, 1x 36, 1x 179
2. trimester															
(380) AFP (MoM)	[MoM]				45								45	40	89%
Samples and groups															
Mother X2		0,191	0,029	15	45		CVP	0,191	0,011	23%	0,147	0,235			45
All results		0,191	0,029	15	45	0									45
Mother Y2		0,865	0,082	9,5	45		CVP	0,865	0,030	23%	0,666	1,07			45
All results		0,865	0,082	9,5	45	0									45
(382) hCG (MoM)	[MoM]				44								36	34	94%
Samples and groups															
Mother X2		3,35	0,53	16	44								36	34	94%
(1) Abbott		3,24	0,096	3,0	5	0	CVPG	3,24	0,27	33%	2,17	4,31			5
(12) Beckman Coulter		3,43	0,51	15	17	0	CVPG	3,43	0,30	33%	2,29	4,57			17
(60) Roche		3,29	0,49	15	14	0	CVPG	3,29	0,32	33%	2,2	4,38			14
Other					8	0									0
															3x 29, 1x 36, 1x 162, 3x 179
Mother Y2		1,04	0,13	13	44								36	36	100%
(1) Abbott		0,975	0,007	0,76	5	0	CVPG	0,975	0,021	33%	0,653	1,3			5
(12) Beckman Coulter		1,06	0,12	11	17	0	CVPG	1,06	0,069	33%	0,71	1,41			17
(60) Roche		1,03	0,15	14	14	0	CVPG	1,03	0,098	33%	0,69	1,37			14
Other					8	0									0
															3x 29, 1x 36, 1x 162, 3x 179
(384) Estriol unconjug. (MoM)	[MoM]				34								33	28	85%
Samples and groups															
Mother X2		0,149	0,033	22	34								33	30	91%
(12) Beckman Coulter		0,148	0,033	22	21	0	CVPG	0,148	0,018	33%	0,099	0,197			21
(29) Siemens (Immulite)		0,143	0,028	19	12	0	CVPG	0,143	0,020	33%	0,095	0,191			12
Other					1	0									0
															1x 999
Mother Y2		0,995	0,14	14	34								33	28	85%
(12) Beckman Coulter		1,02	0,13	13	21	0	CVPG	1,02	0,068	33%	0,683	1,36			21
(29) Siemens (Immulite)		0,945	0,26	28	12	0	CVPG	0,945	0,19	33%	0,633	1,26			12
Other					1	0									0
															1x 999